Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 3/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 3/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.33 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.33 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.33 |
| ▸ | KDM3B | Q7LBC6 | 1/20 | 0.32 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10361694 | 0.68 | ALDH1A1 (0.42) | KDM4EGABRA1GABRB2HTTALDH1A1 | |
| SCHEMBL15304157 | 0.67 | KDM4E (0.43) | KDM4EPOLBCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL10823654 | 0.65 | PDE4A (0.38) | KDM4EHTTCSNK2A2CSNK2BCSNK2A1 | |
| SCHEMBL11467806 | 0.64 | KDM4E (0.56) | KDM4EPOLBHTTDYRK1AALDH1A1 | |
| SCHEMBL23147117 | 0.63 | ALDH1A1 (0.44) | KDM4EGABRA1GABRB2HTTCSNK2A2 | |
| SCHEMBL27962153 | 0.63 | KDM4E (0.53) | KDM4EGABRB2ALDH1A1MEN1KMT2A | |
| SCHEMBL27927329 | 0.63 | GABRA1 (0.52) | GABRA1GABRB2POLB | |
| SCHEMBL2056326 | 0.63 | GABRA1 (0.63) | GABRA1GABRB2POLB | |
| SCHEMBL396402 | 0.62 | GABRA1 (0.73) | KDM4EGABRA1GABRB2POLBHTT | |
| SCHEMBL15558477 | 0.62 | ALDH1A1 (0.36) | KDM4ECSNK2A1KDM3BDYRK1AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9051324-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051324-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| US-9051324-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2015-06-09 | — | — | US | disclosed |
| US-20140073653-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073653-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073653-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-03-13 | — | — | US | disclosed |
| US-8552006-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552006-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-08 | — | — | US | disclosed |
| US-8552006-B2 | Modulators of cystic fibrosis transmembrane conductance regulator | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-10-08 | — | — | US | disclosed |
| EP-2231671-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-04-24 | — | — | EP | disclosed |
| EP-2231671-B1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMA (US) | 2013-04-24 | — | — | EP | disclosed |
| US-20110008259-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-01-13 | — | — | US | disclosed |
| EP-2231671-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | Vertex Pharmaceuticals Incorporated (US) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009076593-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-18 | — | — | WO | disclosed |
| WO-2009076593-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2009-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110008259-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC2 | KDM4E 4314/4885GABRA1 610/4885GABRB2 250/4885 |
| US-20140073653-A1 | MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR | CFTR, ABCB1, ABCC4 | KDM4E 3191/4885GABRA1 937/4885GABRB2 427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.